signed F21 5683 CBER Dec 13 2021 Response Letter

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

2

Document text

DEPARTMENT OF HEALTH  & HUMAN  SERVICES  Public Health Service  
 
 
 
Food  and Drug  Administration  
Rockville, MD 20857 
 
 
December 1 3, 2021 
 
Mr. Aaron Siri  
Siri & Glimstad LLP  
200 Park Avenue  
Seventeenth  Floor  
New York, NY 10166  
 
Sent via email : aaron @sirillp.com  
 
 
Re: FDA FOIA Request 20 21-5683; Public Health and Medical Professionals for Transparency  
v. FDA,  21-cv-01058- P 
 
 
Dear M r. Siri, 
 
This is a partial response to the  Freedom  of Information  Act (FOIA) request number 2021- 5683 that is the 
subject of the  Complaint filed in Public Health and Medical Professionals for Transparency v. FDA , 21-cv-
01058, now pending in the U.S. District Court for th e Northern District of Texas.   
 
Enclosed are 2,890 pages of records, some of which contain redaction to prevent the disclos ure of material 
exempt from the FOIA .   
 In addition to those 2,890 pages , please find enclosed three  txt file s from page 10 and one txt file from page 
11 of the provided Index as you requested in prioritized item number 5.
1  We have also enclosed one xpt  
(SAS) file from page 1 3 and four xpt (SAS) files from page 14 of the Index .2  Because we have assessed that 
there is no exempt material in these txt and xpt files, there have been no deletions to the txt or xpt files.  Per 
your request, we have provided data files in their native format. 
 
We have withheld portions of pages under FOIA Exemption (b)(4), 5 U.S.C. § 552(b)(4).  That exemption permits the withholding of trade secrets and commercial or f inancial information that was obtained from a 
person outside the government and that is privileged or confidential.  
   
 
 
1 Plaintiff provided its priority list of records via two emails from you to Courtney Enlow at the Department of Justice 
on November 4, 2021.  
2 In your request for records listed on page 10 of the Index, you indicated that you were interested in obtaining 
“sample” SAS files.   Although the files listed on page 10 and 11 all may appear to be SAS files, we have determined 
that none of the files listed on page 10 and 11 are SAS files.  As indicated above, we processed three files from page 
10 and one file from p age 11 for this production because you requested a record from page 10.  To accommodate your 
request for sample SAS files, we also processed one xpt (SAS) file that was listed on page 13 and four xpt (SAS ) files 
that were listed on page 14 of the Index, even though you did not prioritize files from pages 13 and 14 of the Index.   
 

 
   We have withheld portions of pages under FOIA Exemption (b)(6), 5 U.S.C. § 552(b)(6).  That exemption protects information from disclosure when its release would cause a clearly unwarranted invasion of personal 
privacy.  FOIA Exemption 6 is available to protect information in personnel or medical files and similar files.  
This requires a balancing of the public’s r ight to disclosure against the individual’s right to privacy.  
 
Please direct any questions regarding this response to  Courtney Enlow  of the Department of Justice, at  
(202) 616- 8467 or  [email protected]
. 
 
 
 
Sincerely,  
 
   Beth Brockner Ryan 
Chief, Access Litigation and Freedom  of Information  Branch  
Division of Disclosure and Oversight Management  
Office of Communication  Outreach and Development  
Center for Biologics Evaluation and Research  
 
Enclosure(s)